Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer.
Drug delivery
IRMOF-3
Liver cancer
Metal-organic frameworks
Norcantharidin
Temperature-sensitive gel
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Jul 2021
14 Jul 2021
Historique:
received:
25
02
2021
revised:
27
04
2021
accepted:
27
05
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
3
8
2021
Statut:
ppublish
Résumé
Norcantharidin (NCTD) is suitable for the treatment of primary liver cancer, especially early and middle primary liver cancer. This compound can reduce tumors and improve immune function. However, the side effects of NCTD have limited its application. There is a marked need to reduce the side effects and increase the efficacy of NCTD. To develop a nanomaterial carrier, NCTD-loaded metal-organic framework IRMOF-3 coated with a temperature-sensitive gel (NCTD-IRMOF-3-Gel), aiming to improve the anticancer activity of NCTD and reduce the drug dose. NCTD-IRMOF-3-Gel was obtained by a coordination reaction. The apparent characteristics and The particle size of NCTD-IRMOF-3-Gel was 50-100 nm, and the particle size distribution was uniform. The release curve showed that NCTD-IRMOF-3-Gel had an obvious sustained-release effect. The cytotoxicity assays showed that the free drug NCTD and NCTD-IRMOF-3-Gel treatments markedly inhibited Hepa1-6 cell proliferation, and the inhibition rate increased with increasing drug concentration. By flow cytometry, NCTD-IRMOF-3-Gel was observed to block the Hepa1-6 cell cycle in the S and G2/M phases, and the thermosensitive gel nanoparticles may inhibit cell proliferation by inducing cell cycle arrest. Apoptosis experiments showed that NCTD-IRMOF-3-Gel induced the apoptosis of Hepa1-6 cells. Our results indicated that the NCTD-IRMOF-3-Gel may be beneficial for liver cancer disease treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Norcantharidin (NCTD) is suitable for the treatment of primary liver cancer, especially early and middle primary liver cancer. This compound can reduce tumors and improve immune function. However, the side effects of NCTD have limited its application. There is a marked need to reduce the side effects and increase the efficacy of NCTD.
AIM
OBJECTIVE
To develop a nanomaterial carrier, NCTD-loaded metal-organic framework IRMOF-3 coated with a temperature-sensitive gel (NCTD-IRMOF-3-Gel), aiming to improve the anticancer activity of NCTD and reduce the drug dose.
METHODS
METHODS
NCTD-IRMOF-3-Gel was obtained by a coordination reaction. The apparent characteristics and
RESULTS
RESULTS
The particle size of NCTD-IRMOF-3-Gel was 50-100 nm, and the particle size distribution was uniform. The release curve showed that NCTD-IRMOF-3-Gel had an obvious sustained-release effect. The cytotoxicity assays showed that the free drug NCTD and NCTD-IRMOF-3-Gel treatments markedly inhibited Hepa1-6 cell proliferation, and the inhibition rate increased with increasing drug concentration. By flow cytometry, NCTD-IRMOF-3-Gel was observed to block the Hepa1-6 cell cycle in the S and G2/M phases, and the thermosensitive gel nanoparticles may inhibit cell proliferation by inducing cell cycle arrest. Apoptosis experiments showed that NCTD-IRMOF-3-Gel induced the apoptosis of Hepa1-6 cells.
CONCLUSION
CONCLUSIONS
Our results indicated that the NCTD-IRMOF-3-Gel may be beneficial for liver cancer disease treatment.
Identifiants
pubmed: 34326620
doi: 10.3748/wjg.v27.i26.4208
pmc: PMC8311525
doi:
Substances chimiques
Antineoplastic Agents
0
Bridged Bicyclo Compounds, Heterocyclic
0
Metal-Organic Frameworks
0
norcantharidin
8452E71EO7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4208-4220Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
Références
Cancer Control. 2018 Jan-Mar;25(1):1073274817744621
pubmed: 29327594
Expert Opin Ther Pat. 2011 Nov;21(11):1743-53
pubmed: 22017412
Pharm Dev Technol. 2017 May;22(3):399-408
pubmed: 27487261
AAPS PharmSciTech. 2018 Jan;19(1):338-347
pubmed: 28733828
J Transl Int Med. 2019 Mar 29;7(1):29-33
pubmed: 30997354
Int J Pharm. 2019 Mar 10;558:291-298
pubmed: 30641178
Exp Ther Med. 2018 Sep;16(3):1639-1646
pubmed: 30186382
Int J Nanomedicine. 2017 Feb 22;12:1465-1474
pubmed: 28260892
Crit Rev Oncol Hematol. 2011 Sep;79(3):251-64
pubmed: 20970353
Biomed Pharmacother. 2020 Nov;131:110755
pubmed: 33152920
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Transl Int Med. 2018 Mar 28;6(1):32-37
pubmed: 29607302
J Drug Target. 2018 Jan;26(1):55-65
pubmed: 28627280
Arzneimittelforschung. 2012 Jun;62(6):290-4
pubmed: 22473525
Artif Cells Nanomed Biotechnol. 2018;46(sup2):1170-1177
pubmed: 29989444
Int J Biol Macromol. 2019 Sep 1;136:1-12
pubmed: 31158420
Cell. 2019 Oct 3;179(2):561-577.e22
pubmed: 31585088
BMC Biotechnol. 2019 Mar 11;19(1):16
pubmed: 30871528
Cancer Sci. 2018 Jul;109(7):2109-2118
pubmed: 29770533
Ther Deliv. 2016 Jun;7(6):359-68
pubmed: 27250538
Yao Xue Xue Bao. 2007 May;42(5):516-9
pubmed: 17703775
Life Sci. 2009 Feb 13;84(7-8):218-26
pubmed: 19100750
Cas Lek Cesk. 2018 Summer;157(4):195-202
pubmed: 30189743
J Transl Int Med. 2018 Oct 09;6(3):128-133
pubmed: 30425948
Evid Based Complement Alternat Med. 2013;2013:461487
pubmed: 23935664
Dalton Trans. 2019 Apr 16;48(16):5308-5314
pubmed: 30938739
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S630-S640
pubmed: 30449176
Oncol Rep. 2018 Aug;40(2):609-620
pubmed: 29901163